Whitehawk Q2 FY26 net loss narrows to $16.64 million
WHWK•Pipeline updates
Phase 1 trials for HWK-007 and HWK-016 continued enrolling; HWK-206 Phase 1 initiation remains on track for Q3 2026.
Cash position strengthens after financing
Cash, cash equivalents and short-term investments rose to USD 190 million at June 30 from USD 145.7 million at Dec. 31, 2025.
CEO Dave Lennon said the company extended its cash runway into 2H 2028 following an upsized financing.
Quarterly loss narrows as R&D spending falls
Whitehawk Therapeutics posted a Q2 net loss of USD 16.6 million, narrowing from USD 52.6 million a year earlier.
R&D spending fell to USD 12.9 million from USD 48.8 million, on the prior-year quarter’s USD 38 million WuXi Biologics up-front license fee.
